Ad-GMCAIX transduced dendritic cells

Next Previous
Drug Profile

Ad-GMCAIX transduced dendritic cells

Alternative Names: DC AdGM CAIX

Latest Information Update: 28 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of California at Los Angeles
  • Developer National Cancer Institute (USA); UCLAs Jonsson Comprehensive Cancer Center
  • Class Antineoplastics; Cell therapies; Vaccines
  • Mechanism of Action Cell replacements; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Renal cell carcinoma

Most Recent Events

  • 28 Mar 2018 No recent reports of development identified for phase-I development in Renal-cell-carcinoma in USA (Intradermal, Injection)
  • 03 Oct 2017 Kite Pharma has been acquired by Gilead Sciences
  • 23 Mar 2016 Phase-I development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top